Literature DB >> 9811732

Residues 231 to 280 of the Epstein-Barr virus nuclear protein 2 are not essential for primary B-lymphocyte growth transformation.

S Harada1, R Yalamanchili, E Kieff.   

Abstract

Epstein-Barr virus (EBV) nuclear protein 2 (EBNA-2) is a transcriptional transactivator of cellular and viral gene expression and is essential for the transformation of resting human B lymphocytes into long-term lymphoblastoid cell lines (LCLs). Previous molecular genetic analyses identified three domains that are critical for transformation and showed that the rest of EBNA-2 is not critical. We now find that codons 231 to 280 that were part of one of the critical domains (J. I. Cohen, F. Wang, and E. Kieff, J. Virol. 65:2545-2554, 1991) can be deleted with only a small effect on the ability of EBNA-2 to transactivate gene expression. In transient transfection assays, EBNA-2 deleted for codons 231 to 280 accumulated to higher levels and was similar to wild-type EBNA-2 in activation of the BamC promoter and in association with RBPJk, a cellular transcription factor that is important for EBNA-2 interaction with promoter regulatory elements. However, EBNA-2 d231-280 activated the viral latent membrane protein 1 (LMP1) promoter with only 60% of wild-type efficiency. Recombinant EBVs specifically deleted for EBNA-2 codons 231 to 280 were efficient in initiating the transformation of resting primary human B lymphocytes into LCLs. However, these LCLs grew less well than wild-type EBV-transformed LCLs, and 4- to 10-fold more cells were required for outgrowth following limit dilution. EBNA-2 d231-280 accumulated to unusually high levels in the recombinant transformed LCLs, and this was associated with somewhat higher EBNA-1 and lower LMP1 expression, consistent with the near-wild-type activation of the BamC EBNA promoter and the abnormally low activation of the LMP1 promoter in transient transfection assays. Thus, EBNA-2 d231-280 modestly perturbed the regulation of viral gene expression and resulted in less LMP1, while having surprisingly subtle effects on LCL outgrowth. Deletion of EBNA-2 codons 292 to 310, which are closer to the site that specifies interaction with RBPJk, was more disruptive of RBPJk association and of the ability to transform B lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811732      PMCID: PMC110508     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation.

Authors:  J I Cohen; F Wang; J Mannick; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

2.  Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene.

Authors:  U Zimber-Strobl; K O Suentzenich; G Laux; D Eick; M Cordier; A Calender; M Billaud; G M Lenoir; G W Bornkamm
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

3.  Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation.

Authors:  J I Cohen; F Wang; E Kieff
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

4.  EBNA-2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus.

Authors:  N S Sung; S Kenney; D Gutsch; J S Pagano
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

5.  Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation.

Authors:  B Tomkinson; E Robertson; E Kieff
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

6.  Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation.

Authors:  K M Kaye; K M Izumi; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

7.  The Epstein-Barr virus immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein.

Authors:  P D Ling; D R Rawlins; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

8.  EBNA-2 of herpesvirus papio diverges significantly from the type A and type B EBNA-2 proteins of Epstein-Barr virus but retains an efficient transactivation domain with a conserved hydrophobic motif.

Authors:  P D Ling; J J Ryon; S D Hayward
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

9.  Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa.

Authors:  T Henkel; P D Ling; S D Hayward; M G Peterson
Journal:  Science       Date:  1994-07-01       Impact factor: 47.728

10.  Epstein-Barr virus gene expression in nasopharyngeal carcinoma.

Authors:  L S Young; C W Dawson; D Clark; H Rupani; P Busson; T Tursz; A Johnson; A B Rickinson
Journal:  J Gen Virol       Date:  1988-05       Impact factor: 3.891

View more
  10 in total

1.  A role for SKIP in EBNA2 activation of CBF1-repressed promoters.

Authors:  S Zhou; M Fujimuro; J J Hsieh; L Chen; S D Hayward
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 2.  The genetic approach to the Epstein-Barr virus: from basic virology to gene therapy.

Authors:  H J Delecluse; W Hammerschmidt
Journal:  Mol Pathol       Date:  2000-10

3.  Epstein-Barr virus nuclear protein 2 has at least two N-terminal domains that mediate self-association.

Authors:  S Harada; R Yalamanchili; E Kieff
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  EBV nuclear antigen EBNALP dismisses transcription repressors NCoR and RBPJ from enhancers and EBNA2 increases NCoR-deficient RBPJ DNA binding.

Authors:  Daniel Portal; Bo Zhao; Michael A Calderwood; Thomas Sommermann; Eric Johannsen; Elliott Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

5.  EBNA2 amino acids 3 to 30 are required for induction of LMP-1 and immortalization maintenance.

Authors:  Alexey V Gordadze; Chisaroka W Onunwor; RongSheng Peng; David Poston; Elisabeth Kremmer; Paul D Ling
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

Review 6.  Molecular virology of Epstein-Barr virus.

Authors:  G W Bornkamm; W Hammerschmidt
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

7.  Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter.

Authors:  L Wang; S R Grossman; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

8.  The residues between the two transformation effector sites of Epstein-Barr virus latent membrane protein 1 are not critical for B-lymphocyte growth transformation.

Authors:  K M Izumi; E D Cahir McFarland; E A Riley; D Rizzo; Y Chen; E Kieff
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

Review 9.  Epstein-Barr virus infection and human malignancies.

Authors:  G Niedobitek; N Meru; H J Delecluse
Journal:  Int J Exp Pathol       Date:  2001-06       Impact factor: 1.925

10.  The EBNA2 polyproline region is dispensable for Epstein-Barr virus-mediated immortalization maintenance.

Authors:  Alexey V Gordadze; David Poston; Paul D Ling
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.